Non-Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Global Osteopathic Treatment for Patients With Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease is a complex disease that is growing more prominent around
the world especially in North America because of high prevalence of overweightness and
obesity. There are many factors that are associated with this illness and it does not seem
to be the same in every patient. The progression of this disease can with time lead to liver
cirrhosis and even primary liver cancer (hepatocellular carcinoma). Currently, the only
treatment plan involves diet change and exercise.
The goal of this research is to validate that Osteopathy can optimise patient health and to
potentially be another option in preventing/reducing progression of this disease. This
research is important for the future of Osteopathy to educate the public and other
therapists/physicians the benefits this manual therapy has to offer. Previous research has
been done and shown that Osteopathy can help patients with low back pain and type two
diabetes, by affecting glucose and insulin levels with manipulation of the spine and
pancreas.
Another study compared one group of obese patients with chronic low back pain that just did
specific exercises to another group that were given exercises as well as Osteopathic manual
therapy (OMT). Results showed both groups had reduced pain, however only the group with
additional OMT showed improved range of motion in the thoracic spine, and showed greater
degree of improvement overall for these patients. This study shows how OMT can be effective
for individuals with NAFLD for in general these patients are obese and part of their
treatment regime is to exercise to lose weight. The researcher could not find any previous
research on OMT contributing to weight loss, however according to the Reve Pavilion natural
health clinic website (2015), OMT can improve underlying issues such as low back pain,
preventing the person to exercise effectively. The researcher also hopes to gain further
knowledge of this subject, and to show the benefits of collaborating Osteopathy and
Allopathic medicine together to obtain optimal patient care.
Randomized Quantitative Clinical Trial. There will be 48 participants randomly assigned
codes numbers and placed into a treatment group or non treatment group with 24 candidates in
each. The control group will not be receiving treatments whereas the experimental group will
be receiving four global osteopathic treatment over a six week period. All participants in
both groups will have a baseline blood work provided by Dr. Peltekian a month before
commencement of treatment. These patients have routine blood work every three months to
begin with so they will get their second bloodwork done after the treatment sessions.
Each group will also fill out the Chronic liver disease questionnaire to measure quality of
life and the URICA to measure their readiness to change a week before the first treatment,
and a week after the last treatment session.
The study objectives is to observe a difference between blood work pre and post treatment
that osteopathy has influenced and improved liver function based on liver enzyme count. Also
to observe an improvement in the patients quality of life after receiving treatment and in
their readiness to change. The researcher hopes to validate osteopathy as another treatment
option to give NAFLD patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
| Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
| Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
| Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
| Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
| Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
| Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
| Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
| Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
| Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
| Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
| Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
| Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
| Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
| Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
| Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |